IN8bio reports FY2022 net loss $28.5M; cash $18.2M; clinical data positive

IN8BIO, INC.

Cash $18.2M at Dec 31, 2022, down from $37.0M a year earlier; R&D spend $14.1M (FY2022) vs $7.3M.
Net loss $28.5M ($1.36/share) for FY2022 vs $14.7M ($1.47/share) in FY2021; Q4 loss $7.8M ($0.32/share).
INB-100 leukemia patients maintain durable complete responses beyond 18 months, up to 2.7 years in Phase 1.
INB-200 GBM trial: two patients progression-free at 1.5 and 1.2 years; enrolling Cohort 3; updated data mid-2023.
FDA cleared IND for INB-400 Phase 2 trial in GBM; enrollment expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IN8BIO, INC. reported financial results for the fourth quarter and full-year ended December 31, 2022.

Period: the fourth quarter and full-year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, IN8bio, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-010956

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.